Ying-Nan Liu

Ying-Nan Liu

Auto-generated profile, based on publicly available information

Ying-Nan Liu

Tumor Etiology and Screening Department of Cancer Institute and General Surgery The First Hospital of China Medical University Shenyang PR China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ALAo-Ran Liu
Ao-Ran Liu
YLYing-Nan Liu
Ying-Nan Liu
SSShi-Xuan Shen
Shi-Xuan Shen
LYLi-Rong Yan
Li-Rong Yan
ZLZhi Lv
Zhi Lv
QXQian Xu
Qian Xu
As the largest gene family functioning in protein transport among human solute carriers, the SLC25 family (mitochondrial carrier family) can participate in development of cancer. However, a comprehensive exploration for the exactly roles of SLC family remains lacking. In the present study, a total of 15 functional SLC25 family genes were retrieved from all current publications. And multidimensional analyses were systematically performed based on the transcriptome and genome data of SLC25 family from a variety of online databases for their expression, immune cell infiltration, and cancer prognosis. Validation by qPCR and immunohistochemistry were further conducted for the expression of partial SLC25 family members in some tumor tissue. We found that the SLC25 family had strong correlation with immune cells, such as macrophages M2, CD8+ T cell, CD4+ T cell memory activated, and memory resting. Among them, SLC25A6 was most correlated with Macrophage M1 in uveal melanoma (r = −0.68, P = 1.9e − 0.5). Expression of mRNA level showed that SLC25A4 was downregulated in stomach adenocarcinoma and colon adenocarcinoma. SLC25A7 was highly expressed in stomach adenocarcinoma and colon adenocarcinoma. SLC25A23 was decreased in colon adenocarcinoma. qPCR and immunohistochemistry validation results were consistent with our bioinformatics prediction. SLC25A8 was associated with the prognosis of cancer. All these findings suggested that the SLC25 family might affects the immune microenvironment of the cancer and then had the potential to be predictive biomarkers for early diagnosis and prognosis as well as novel targets for individualized treatment of cancer.

22 October 2026 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
PDF file
YLYing‐Nan Liu
Ying‐Nan Liu
BWBen Wang
Ben Wang
QXQian Xu
Qian Xu
In the personalized management of stage II colorectal cancer (CRC), traditional TNM (Tumor, Node, Metastasis) staging has limited ability to accurately stratify the risk of postoperative recurrence. Consequently, oncologists frequently face a major therapeutic dilemma when determining the use of adjuvant chemotherapy in these patients. Although tumor budding (TB) has been incorporated into international clinical guidelines as an independent prognostic marker associated with invasive potential, the conventional International Tumor Budding Consensus Conference classification system is primarily based on routine hematoxylin and eosin (H&E) staining. Furthermore, this framework classifies tumors with 0–4 buds into a single low‐risk category termed Bd1. This classification may obscure important biological differences between tumors with complete absence of cellular dissociation and those already showing early invasive activity. This review proposes separate diagnostic recognition of the ‘zero‐budding’ (Bd0) category. Recent large‐scale cohort studies and retrospective analyses support that Bd0 status, particularly when confirmed by pan‐cytokeratin immunohistochemistry, is associated with an extremely high negative predictive value for postoperative recurrence. At the subcellular level, the Bd0 category may reflect sustained suppression of the epithelial–mesenchymal transition process. Mechanistically, this relatively non‐invasive category may be maintained by preservation of the EBP50 scaffold, which stabilizes the membranous E‐cadherin/beta‐catenin complex and suppresses nuclear translocation of Wnt/beta‐catenin. Bd0 is also strongly associated with the deficient mismatch repair microenvironment, in which high tumor mutational burden may promote enhanced CD8 + T cell‐mediated immune surveillance capable of eliminating disseminating tumor cells before morphologic budding becomes detectable. This review summarizes the evolution of TB assessment, reviews the available clinical evidence supporting Bd0, evaluates emerging diagnostic approaches, and discusses the underlying molecular mechanisms.